Middle East & Africa T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)
The Middle East & Africa T cell therapy market was valued at US$ 73.14 million in 2022 and is expected to reach US$ 211.46 million by 2030; it is estimated to grow at a CAGR of 14.2% from 2022 to 2030.
Rising Number of CAR T-Cell Therapies in Clinical Trials Fuels the Middle East & Africa T Cell Therapy Market
The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.
• In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.
• JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
• Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).
• ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
• Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment.
Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the Middle East & Africa T-cell therapy market.
Middle East & Africa T Cell Therapy Market Overview
The T-cell therapy market in the Middle East & Africa is segmented into Israel, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The T-cell therapy market in the Middle East & Africa is anticipated to grow due to the approval of CAR T-cell therapies and increasing healthcare expenditure. In September 2022, Gilead and Kite established a fully functional cell therapy business unit after the regulatory approval of T-cell therapies such as Yescarta and Tecartus. T-cell therapies will soon be available for the Saudi Arabian population. According to an article published by the National Library of Medicine, CAR T-cell therapy is not yet approved in the UAE; however, it is expected to be approved within the next 2 years.
Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Middle East & Africa T Cell Therapy Market Segmentation
The Middle East & Africa T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the Middle East & Africa T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Middle East & Africa T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Middle East & Africa T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Middle East & Africa T cell therapy market is segmented into Saudi Arabia, Israel, and Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Middle East & Africa T cell therapy market.
Rising Number of CAR T-Cell Therapies in Clinical Trials Fuels the Middle East & Africa T Cell Therapy Market
The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.
• In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.
• JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
• Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).
• ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
• Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment.
Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the Middle East & Africa T-cell therapy market.
Middle East & Africa T Cell Therapy Market Overview
The T-cell therapy market in the Middle East & Africa is segmented into Israel, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The T-cell therapy market in the Middle East & Africa is anticipated to grow due to the approval of CAR T-cell therapies and increasing healthcare expenditure. In September 2022, Gilead and Kite established a fully functional cell therapy business unit after the regulatory approval of T-cell therapies such as Yescarta and Tecartus. T-cell therapies will soon be available for the Saudi Arabian population. According to an article published by the National Library of Medicine, CAR T-cell therapy is not yet approved in the UAE; however, it is expected to be approved within the next 2 years.
Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Middle East & Africa T Cell Therapy Market Segmentation
The Middle East & Africa T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the Middle East & Africa T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Middle East & Africa T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Middle East & Africa T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Middle East & Africa T cell therapy market is segmented into Saudi Arabia, Israel, and Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Middle East & Africa T cell therapy market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance9
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Middle East & Africa T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MIDDLE EAST & AFRICA T CELL THERAPY MARKET LANDSCAPE
4.1 Overview
5. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Growing Burden of Cancer Worldwide
5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:
6. T CELL THERAPY MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
7. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY
7.1 Overview
7.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
7.3.1 Overview
7.3.2 Research: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
7.4.1 Overview
7.4.2 Commercialized: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
8.1 Overview
8.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
8.3.1 Overview
8.3.2 CAR T-cell Therapy: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based.
8.4.1 Overview
8.4.2 T-cell Receptor (TCR)-based: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
9.1 Overview
9.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
9.3.1 Overview
9.3.2 Hematologic Malignancies: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Middle East & Africa T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
9.4 Solid Tumor
9.4.1 Overview
9.4.2 Solid Tumor: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
10. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - COUNTRY ANALYSIS
10.1 Overview
10.1.1.1 Middle East & Africa T Cell Therapy Market, by Country
10.1.1.2 Saudi Arabia
10.1.1.2.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.2 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.2.3 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.2.4 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.2.4.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.1.1.3 Israel
10.1.1.3.1 Israel: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.2 Israel: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.3.3 Israel: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.3.4 Israel: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.3.4.1 Israel: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.1.1.4 Rest of Middle East & Africa
10.1.1.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.2 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.4.4 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.4.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
11. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Legend Biotech Corp
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Janssen Global Services LLC
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Gilead Sciences Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bristol-Myers Squibb Co
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Novartis AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance9
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Middle East & Africa T Cell Therapy Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MIDDLE EAST & AFRICA T CELL THERAPY MARKET LANDSCAPE
4.1 Overview
5. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Growing Burden of Cancer Worldwide
5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:
6. T CELL THERAPY MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
7. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY MODALITY
7.1 Overview
7.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
7.3.1 Overview
7.3.2 Research: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
7.4.1 Overview
7.4.2 Commercialized: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY THERAPY TYPE
8.1 Overview
8.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
8.3.1 Overview
8.3.2 CAR T-cell Therapy: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based.
8.4.1 Overview
8.4.2 T-cell Receptor (TCR)-based: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - REVENUE AND FORECAST TO 2030 - BY INDICATION
9.1 Overview
9.2 Middle East & Africa T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
9.3.1 Overview
9.3.2 Hematologic Malignancies: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Middle East & Africa T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
9.4 Solid Tumor
9.4.1 Overview
9.4.2 Solid Tumor: Middle East & Africa T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
10. MIDDLE EAST & AFRICA T CELL THERAPY MARKET - COUNTRY ANALYSIS
10.1 Overview
10.1.1.1 Middle East & Africa T Cell Therapy Market, by Country
10.1.1.2 Saudi Arabia
10.1.1.2.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.2 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.2.3 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.2.4 Saudi Arabia: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.2.4.1 Saudi Arabia: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.1.1.3 Israel
10.1.1.3.1 Israel: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.2 Israel: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.3.3 Israel: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.3.4 Israel: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.3.4.1 Israel: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.1.1.4 Rest of Middle East & Africa
10.1.1.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.2 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
10.1.1.4.4 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
10.1.1.4.4.1 Rest of Middle East & Africa: Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
11. T CELL THERAPY MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Legend Biotech Corp
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Janssen Global Services LLC
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Gilead Sciences Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bristol-Myers Squibb Co
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Novartis AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
